Heidi Kay is the Founder and CEO of Jericho Sciences, LLC. She holds a strong patent portfolio in therapeutics and has extensive experience in disease models. She is the lead inventor for novel antiviral and anticancer therapeutic molecules and associated diagnostic methods.
Dr. Kay’s research focus is toward curative strategies for HIV-1 infection, including strategies for long term remission of virus-associated pathologies. This work has been supported through federal NIH small business funding since 2010, following the founding of Jericho Sciences in 2009.
Dr. Kay earned her Ph.D. in physical chemistry in 1999 at the University of South Florida (Tampa) under the Distinguished Professor, Dr. Brian Stevens. With over 30 years of research and biotechnology experience, Dr. Kay is committed and determined to improve therapeutic management of HIV infection for the millions of individuals globally affected.
Esther Alegria is a Senior Executive Biopharmaceutical Advisor at Catalyst Excel & Advance, lending her expertise from over 28 years’ experience in research, development and commercialization expertise to pharmaceutical companies. Prior to becoming a Senior Executive Advisor she was the Senior Vice President (SVP) of Global Manufacturing at Biogen, where she was responsible for the company’s successful manufacturing operations in Denmark, Massachusetts and North Carolina. These facilities cover world-class biopharmaceutical large-scale drug substance, medical device assembly, finished goods and small molecule manufacturing operations. Prior to her role as SVP, Esther was the Vice President of Manufacturing and General Manager of Biogen Idec’s Research Triangle Park, North Carolina site, and moved to Hillerød, Denmark to lead the start-up of a second large scale facility, bringing it to commercial manufacturing licensure.
Business NC Magazine selected Esther in 2009 as Woman Extraordinaire of the Year for being an influential leader within her company and for her impact on its economic success and forward-thinking strategies. Esther holds a Ph.D. in Chemistry from the University of Hawaii and an Executive Business Management certification from Harvard Business School.
Mark Zorko is a CPA and is on the Board and Chair of the Audit Committee for Westell Technologies (NASDAQ: WSTL). He previously chaired Nominating/Governance, Audit and the Strategic Advisory Committees of Perma Pipe International Holdings (NASDAQ: PPIH), in addition to several private company Boards.
He has been a CFO and CIO for manufacturing, business service, health care and high-tech firms. His background includes over 20 years of Board experience. He has also been the interim CEO of Well Services Ltd.
Mark served on the Audit Committee for Opportunity International and on the Board of Directors for St. Alexius Medical Center in Chicago. Mark began his career at Arthur Andersen and Honeywell in the U.S. and Europe. He received his MBA in IT from the University of Minnesota and his BS in Accounting from The Ohio State University.
Deanna Kulpa received her doctoral degree in Human Genetics while studying reverse transcription of human non-LTR retrotransposons at the University of Michigan. Dr. Kulpa performed postdoctoral studies first with Dr. Kathleen Collins, focusing on mechanisms of immune system evasion by HIV, and then with Dr. Rafick Sékaly focusing on development of in vitro and ex vivo assays to study HIV latency. Currently, Dr. Kulpa is an Assistant Professor at the Emory University School of Medicine in the Department of Pathology and at the Yerkes National Primate Research Center in the Division of Microbiology and Immunology .
Dr. Kulpa’s research focuses on defining the mechanisms that promote HIV persistence in antiretroviral therapy-treated, HIV-infected individuals. Her goal is to identify and evaluate therapeutic strategies to provide a foundation for designing clinical studies aimed at eradicating HIV. Dr. Kulpa is a member of the Emory Center for AIDS Research and is on the editorial board of the Journal of Virology.